The serum levels of eosinophil cationic protein (ECP) are related to the infiltration of eosinophils in the tumours of patients with Hodgkin's disease

被引:19
作者
Molin, D [1 ]
Glimelius, B [1 ]
Sundström, C [1 ]
Venge, P [1 ]
Enblad, G [1 ]
机构
[1] Uppsala Univ, Sect Oncol, Dept Oncol Radiol & Clin Immunol, Univ Uppsala Hosp, S-75185 Uppsala, Sweden
关键词
Hodgkin's disease; eosinophil cationic protein (ECP); eosinophilic granulocytes; prognosis;
D O I
10.3109/10428190109064602
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have previously described a relation between abundance of eosinophilic granulocytes in Hodgkin's disease (HD) tumours and poor prognosis. In order to further explore the importance of the eosinophilic infiltration, we immunohistochemically examined the presence of eosinophils, using the monoclonal antibodies EG 1 and EG 2, in the tumours of 54 newly diagnosed patients with HD and related the degree of infiltration to clinical characteristics and the serum levels of eosinophil cationic protein (S-ECP). S-ECP levels (upper normal value 16 mug/l) varied between 2.2 and 71.7 mug/l, mean 25.4 mug/l. There was an association (p = 0.01) between the number of eosinophils in the tumour tissue and S-ECP. S-ECP levels were also associated to high erythrocyte sedimentation rate (ESR, p < 0.01) and nodular sclerosis (NS) histology (p < 0.05), and there was a tendency of a correlation to bulky disease (p = 0.06). The number of eosinophils stained with EG 2 correlated to high ESR (p < 0.05), and to high leukocyte count (p = 0.02). A follow-up value of S-ECP after treatment was, in most of the cases measured, lower than the initial value. The high values of S-ECP in several patients with HD probably originates from eosinophils infiltrating the tumours. The same patients had a higher ESR and tended to have a more advanced stage and bulky disease. There are no significant correlations with disease-free and overall survival, as the follow-up time is short, and prognosis favourable.
引用
收藏
页码:457 / 465
页数:9
相关论文
共 35 条
[1]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[2]   IMMUNOENZYMATIC LABELING OF MONOCLONAL-ANTIBODIES USING IMMUNE-COMPLEXES OF ALKALINE-PHOSPHATASE AND MONOCLONAL ANTI-ALKALINE PHOSPHATASE (APAAP COMPLEXES) [J].
CORDELL, JL ;
FALINI, B ;
ERBER, WN ;
GHOSH, AK ;
ABDULAZIZ, Z ;
MACDONALD, S ;
PULFORD, KAF ;
STEIN, H ;
MASON, DY .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1984, 32 (02) :219-229
[3]  
DESENNE JJ, 1992, CANCER, V69, P1248, DOI 10.1002/cncr.2820690529
[4]   INFILTRATION OF EOSINOPHILS IN HODGKINS-DISEASE INVOLVED LYMPH-NODES PREDICTS PROGNOSIS [J].
ENBLAD, G ;
SUNDSTROM, C ;
GLIMELIUS, B .
HEMATOLOGICAL ONCOLOGY, 1993, 11 (04) :187-193
[5]  
Endo M, 1995, ANN HEMATOL, V71, P313, DOI 10.1007/BF01697986
[6]   DETERMINATION OF EOSINOPHIL CATIONIC PROTEIN IN URINE BY AN ENZYME-IMMUNOASSAY [J].
FRANDSEN, B ;
LOSE, G .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1986, 46 (07) :629-634
[7]   A QUANTITATIVE STUDY OF EOSINOPHIL POLYMORPHS IN HODGKINS-DISEASE [J].
FUGGLE, WJ ;
CROCKER, J ;
SMITH, PJ .
JOURNAL OF CLINICAL PATHOLOGY, 1984, 37 (03) :267-271
[8]   Treatment of Hodgkin's disease: The Swedish national care programme experience [J].
Glimelius, B ;
Enblad, G ;
Kalkner, M ;
Gustavsson, A ;
Jakobsson, M ;
Branehog, I ;
Lenner, P ;
Bjorkholm, M .
LEUKEMIA & LYMPHOMA, 1996, 21 (1-2) :71-78
[9]  
GRUSS HJ, 1994, LEUKEMIA, V8, P2083
[10]  
GRUSS HJ, 1994, BLOOD, V83, P2045